Healthcare / Medical DevicesShanghai
$30.94
-0.67 (-2.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $148.6M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.8B
P/E
44.2x
↑EV/EBITDA
22.7x
↑ROE
5.7%
↑Gross Margin
46.8%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.7%
FCF CAGR
-24.0%
FCF margin
6.4%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.33B · net income $250.7M · FCF $148.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.33B | $2.33B | $2.28B | $2.28B | $2.86B |
| Net Income | $250.7M | $250.7M | $366.6M | $406.1M | $600.8M |
| EBITDA | $394.2M | $394.2M | $525.9M | $541.4M | $742.2M |
| EPS | 0.80 | 0.80 | 1.16 | 1.28 | 1.89 |
| Gross Margin | 46.8% | 46.8% | 48.0% | 48.6% | 48.2% |
| Operating Margin | 10.1% | 10.1% | 15.0% | 14.7% | 20.8% |
| Net Margin | 10.8% | 10.8% | 16.1% | 17.8% | 21.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 2.45 | 2.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $148.6M | $148.6M | $165.0M | $72.1M | $338.2M |
| Returns | |||||
| ROE | 5.7% | 5.7% | 8.4% | 9.6% | 14.9% |
| Valuation | |||||
| P/E | 44.20 | 44.20 | 30.34 | 30.17 | 34.52 |
| EV/EBITDA | 22.70 | 22.70 | 19.50 | 20.34 | 26.71 |
| P/B | 2.22 | 2.22 | 2.54 | 2.90 | 5.16 |
| Growth & Yield | |||||
| Revenue Growth | 2.0% | 2.0% | 0.1% | -20.4% | — |
| EPS Growth | -31.0% | -31.0% | -9.4% | -32.3% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
50.8%
EPS terminal req.
$2.75
Spread vs growth
-81.9%
5Y implied EPS CAGR
32.9%
EPS terminal req.
$3.32
Spread vs growth
-64.0%
10Y implied EPS CAGR
20.9%
EPS terminal req.
$5.35
Spread vs growth
-52.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.9%
Start / end P/E
27.3x → 38.7x
EPS bridge
1.16 → 0.80
Residual
-12.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.